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EXECUTIVE SUMMARY
The Commission adopted its Programme for Action (PfA), entitled Accelerated action on
HIV/AIDS, malaria and TB in the context of poverty reduction in February 2001. The PfA
entailed a series of actions to increase the impact of existing interventions, increase the
affordability of key pharmaceuticals, and encourage research in and development of
specific global public goods to tackle HIV/AIDS, malaria and TB at the national, regional
and global level. The PfA has been in place for two years and it is now an appropriate
juncture at which to assess its implementation, outstanding policy issues and future
challenges.
The PfA, and its implementation, is important above all because the number of people
affected, infected and dying from HIV/AIDS, malaria and TB is still on the increase. In 2001
alone, some three million people died from AIDS, while another five million were newly
infected by HIV. The burden of malaria and tuberculosis continues also to increase. In 2001,
some two million people died from TB and 1 million from malaria. Current trends indicate
that by 2020 nearly one billion people will have become infected with TB, 200 million will
have developed the disease and 35 million of them will have died. Both TB and malaria are
contributing factors in another two to four million deaths annually.
There is a consensus within the international community about the urgency of the need to
tackle HIV/AIDS, malaria and TB in developing countries and about the mechanisms by
which this can be achieved. All members of the international community have signed up to
the Millennium Development Goals (MDGs). HIV/AIDS, malaria and TB targets feature
prominently, highlighting the link between overall poverty reduction and health investments.
The WHO-initiated Commission on Macroeconomics and Health (CMH) presented
convincing evidence of the need to focus on the three diseases and demonstrated why
investments in health are an effective strategy for reducing poverty. The debate over Global
Public Goods (GPGs) has also advanced and appropriate incentives are being considered for
the production of specific GPGs, such as controlling the HIV/AIDS, malaria and TB
epidemics. There is still no HIV/AIDS, malaria or, effective, TB vaccine available and many
of these global public goods depend on international action.
With regard to ‘increasing impact’, progress has been slow in terms of increased support for
health. Notwithstanding the large price reductions obtained since the adoption of the PfA,
only few have access to anti-retroviral medicines, effective TB and malaria interventions. The
desired increase of health spending in developing countries to at least USD 30-40 per person
per annum, will require, by 2007, approximately USD 27 billion per annum in donor grants
5and an additional budgetary outlay from developing countries of USD 23 billion. An estimate
of annual financial needs to cover HIV/AIDS, malaria and TB alone totals USD 9.2 billion.
The results of the effectiveness of the PfA at country level need to be assessed over a longer
time-scale. However, EC spending on social infrastructure is planned to rise, dormant
programmes have been re-directed, and spending better focused on those priorities established
by the PfA. At EU level several resolutions have been adopted by Council and Parliament
confirming the priorities established by the PfA. The Commission has also adopted a
Communication on Health and Poverty, which identifies four broad approaches toward
improving health outcomes, and proposed a Regulation on Poverty Diseases (HIV/AIDS,
malaria and TB). The latter includes a substantial increase in financial resources.
With regard to ‘increasing affordability’, intellectual property rights and the TRIPs
Agreement have caught a lot of attention in the launching of the new WTO Development
Round. At the Ministerial meeting of WTO Members at Doha in 2001, the adoption of the
Declaration on relations between the TRIPs Agreement and Public Health was a significant
step forward. The Commission’s strategy towards tiered pricing for improved supplies of
essential pharmaceuticals to developing countries has also yielded tangible results. During the
last two years the tiered pricing concept has gradually become widely accepted within the EU
as an effective way forward in the quest for access to key pharmaceutical products for people
living in poverty. In this regard, the Commission has adopted a proposal for a Council
Regulation to prevent trade diversion into the EU market of pharmaceuticals sold at tiered
prices in developing countries.
In terms of ‘increasing investment in research and development’, substantial resources
have been allocated from the Research Framework Programmes for HIV/AIDS, malaria and
TB research, including the establishment of the new European and Developing countries
Clinical Trials Partnership (EDCTP) initiative. The EDCTP clearly constitutes a new step
forward as it contributes to a unified voice to represent European research contributions in the
fight against the three diseases in developing countries. Additional direct and indirect
incentives for research and development of specific global public goods to fight the three
diseases require primary focus in the coming years.
Globally, the EC has been proactive in addressing the issues covered by the PfA, for example,
in the context of the G8, in particular at Okinawa, at EU/US summits, the EU/OAU forum.
The Commission is an active Board Member of the Global Fund to fight AIDS, TB and
Malaria (GFATM). Developing countries have a strong voice in the GFATM Board and the
Fund’s overall governance arrangements. Important policy areas, which had previously not
been successfully addressed in other fora such as tiered pricing, are being addressed here.
These can, however, not be dealt with in the GFATM alone. Renewed efforts are needed to
work jointly at the European level as well as with specific partners, in particular the US, on
these issues.
Two years after its adoption the PfA remains a comprehensive, forward looking and
coherent EU policy framework aimed at making a significant contribution towards
improved country, regional and global action against the three communicable diseases.
There is, however, still an urgent need for large-scale collective action. Where progress has
been less visible, it is mainly the result of the lack of appropriate resources within the
Commission and/or within the Member States to take forward large scale action in areas such
as local -production- capacity, technology transfer, incentives for innovative research and
development by the private sector, and working through true partnerships in particular with
the developing countries concerned.
6The PfA has demonstrated that a strong EU voice is crucial, and, as a result of the PfA, EU
positions on targeted HIV/AIDS, malaria and TB actions have been significantly strengthened
on a global level jointly with other partners. Nevertheless, more efforts are needed to provide
regular and structured consultation with developing countries. It is proposed that this be
further developed through the creation of a Stakeholders Forum on Communicable
Diseases in the Context of Poverty Reduction.
Major challenges lie ahead for the EU in getting developing countries, other OECD members,
their industry and civil society to adopt and apply the different mechanisms needed to fight
the three diseases.
71. INTRODUCTION
The EC Programme for Action on Communicable Diseases in the Context of Poverty
Reduction (hereinafter Programme for Action or PfA) is based on the policy framework
presented in the September 2000 Communication on “Accelerated Action targeted at major
communicable diseases within the context of poverty reduction”1. It establishes, as part of an
expanded international effort, a broad and coherent Community response, over the period
2001 to 2006, to the global emergency caused by the three major communicable diseases,
HIV/AIDS, malaria and tuberculosis (TB). These diseases affect the poorest populations most
and undermine global health and sustainable development. The Community response entails a
comprehensive and mutually reinforcing set of actions to increase: (i) the impact of existing
interventions, (ii) the affordability of key pharmaceuticals, and (iii) research and development
of specific global public goods to confront HIV/AIDS, malaria and TB at the national,
regional and global levels.
This Communication assesses the implementation of the PfA over the first two years of its
existence. It is intended primarily for Council and European Parliament. It is also important
for the broader public committed to contributing to improved sustainable development
outcomes to be aware of the progress made in the joint fight against the three diseases in
developing countries. The document addresses the overall context and the outstanding
challenges globally, and presents results in the areas of impact, affordability and research. A
separate section is devoted to 'monitoring and evaluation', followed by recommendations for
the future.
2. CONTEXT AND CHALLENGES
In all, over the past two years, more than 160 million healthy life years have been lost to HIV,
80 million to malaria and nearly 72 million to tuberculosis
1. The number of people affected, infected and dying from HIV/AIDS, malaria and
TB is still on the increase. In 2001 alone, some three million people died from
AIDS, while another five million contracted HIV. Half of all new HIV infections -
over 6,000 daily - occur among 15-24 year olds. The areas with the most rapid spread
are in Eastern Europe, Central Asia, China and India. Most new infections in these
areas are among injecting drug users. Yet overall, AIDS remains a major factor in all
regions.
2. The development burden of malaria and TB also continues to increase. Current
trends indicate that by 2020 nearly one billion people will have become infected with
TB, 200 million will have developed the disease and 35 million of them will have
died. One-third of the world's population is currently infected with tuberculosis. In
2001, some two million people died from TB and 1 million from malaria. Both TB
and malaria are contributing factors in another two to four million deaths annually.
The majority of malaria deaths occur among young children living in Sub-Saharan
                                                
1 COM (2001) 96 of 21.2.2001 and COM(2000) 585 of 20.9.2000.
8Africa. TB is predominantly linked to the large prevalence of AIDS and is a major
factor in South East Asia, East Asia, the Pacific and the Americas.
2.1. Unprecedented international agreement - starting to reconcile the
contradictions
1. The past two years have been marked by a widespread consensus within the
international community about the urgency of the need to tackle HIV/AIDS, malaria
and TB in developing countries and about mechanisms through which this can be
achieved. More than ever before, government officials, politicians, policy and
decision-makers, civil society actors and business executives, have become aware of
the burden caused by these diseases, and how it will develop if we do not scale up
our efforts to fight them. This consensus has led to a new political momentum, which
has garnered unprecedented international agreement on the interventions that will
make the greatest difference.
2. All members of the international community have signed up to the Millennium
Development Goals (MDGs – Annex 3). Central to these goals is a reduction in the
proportion of people living in extreme poverty by 50% by 2015. Health targets
feature prominently, highlighting the link between overall poverty reduction and
health investments. The specific Goal 6 related to 'HIV/AIDS, malaria and other
diseases' indicates a strong commitment, acknowledging that without addressing
these diseases the central outcome of global poverty reduction will not be met.
Specifically, the aim is to halt and reverse the spread of HIV/AIDS and the incidence
of malaria and TB by 2015. It is now generally accepted that the PfA has directly
contributed to the international consensus reached on MDG Goal 6.
3. Other more specific targets have been agreed upon globally or regionally for the
three diseases: for HIV/AIDS at the UN General Assembly Special Session on
HIV/AIDS in June 2001, for malaria at the African Summit on Roll Back Malaria in
Abuja in April 2000, and for tuberculosis, inter alia at the World Health Assembly of
May 2000. The goals, targets, accompanying indicators and measures for the three
diseases are also being addressed in the newly established Global Fund to fight
HIV/AIDS, malaria and tuberculosis (GFATM).
4. Another important global turning point during the past two years was the work
undertaken by the WHO Commission on Macroeconomics and Health (CMH)2.
The report presents clear evidence of how a heavy disease burden3 reduces economic
growth and limits the resources available to governments to invest in public health
and poverty reduction efforts. It demonstrated why increased investments in health
constitute an effective strategy for reducing the number of people living in poverty
and estimates the return on health investments in developing countries at 18% per
annum. The CMH helped strengthen a global consensus on the need to reduce the
disease burden of people living in poverty through concentrating on these three
diseases.
                                                
2 WHO Commission on Macroeconomics and Health, Final report December 2001.
3 The impact of ill health on individuals, and on their societies, is measured by estimating the number of
years of healthy life they lose as a result of each illness. Cumulatively, the total number of healthy life
years lost as a result of the illness can be described as the "disease burden" that it causes. The total
disease burden in a society represents the gap between the actual health of the population and an ideal
situation where everyone lives into old age in full health.
95. Since the adoption of the PfA the debate over Global Public Goods (GPGs) has
advanced further in different fora. The PfA was a clear statement of the need for a
global GPG policy approach based on the understanding that investments in health
and development are in the interests of all, poor and rich. This policy approach goes
far beyond mere “aid”. Since providers of public goods may not be adequately
compensated through market-based negotiations or through existing public financing
mechanisms, the EC and the EU Member States are now working on developing
appropriate incentives for the production of specific GPGs (products, services,
knowledge) able to help controlling epidemics such as HIV/AIDS, malaria and TB.
6. A growing body of evidence shows that prevention, treatment and care are parts of
a continuum. Equally, it is increasingly apparent that it is possible to deliver care and
treatment for people with AIDS in resource-poor settings, which is an important part
of efforts to make prevention more effective. This growing perception was apparent
during the UNGASS on HIV/AIDS in June 2001, and resulted in a consensus that
prevention and treatment should be addressed as complementary, not competing
priorities during the XIV International Conference on AIDS, in July 2002. The
essential link between prevention and care is also common knowledge in the field of
TB control since only 80% cure rate in a highly endemic community can control
transmission. There is increasing evidence that a similar link is strong in the field of
malaria, in particular for malaria control in pregnant women, as it is often fatal for
the mother or the child.
7. There continues to be strong public interest in the need to promote and improve
access to medicines in poor countries. An important focus of public campaigning
has been to establish a better relationship between the protection of public health and
the protection of intellectual property rights enjoyed by pharmaceutical
manufacturers. At the Doha Ministerial Meeting in 2001, World Trade Organisation
(WTO) members successfully negotiated a Declaration regarding the interpretation
and implementation of the relationship between the TRIPs Agreement and Public
Health “…in a manner supportive of WTO Members right to protect public health
and in particular to promote access to medicines for all”. The European Community
and its Member States played a decisive role in achieving agreement on this
Declaration, and continue to lead subsequent negotiations on outstanding issues.
2.2. Globally slow progress on ‘access’ and ‘resource mobilisation’
1. Despite the above, however, progress has been slow in terms of the urgency of
delivering quality prevention, treatment and care services, including commodities
and supplies. This was one of the central elements of the PfA. There is overall
agreement that appropriate use of condoms and prevention of mother to child
transmission with anti-retrovirals could halt the spread of the HIV/AIDS pandemic,
while Highly Active Antiretroviral Treatment (HAART) has proven to be life-saving
in many cases and an incentive for effective prevention through an increased uptake
of voluntary counselling and testing, and through health information and education in
general. Whilst during the last two years the prices of anti-retroviral drugs (ARVs)
and some drugs against opportunistic infections have started to fall, in some cases by
large margins (annex 4), and countries such a Brazil have progressed substantially in
providing overall access to pharmaceuticals for HIV infected people, it remains the
case that only 0.3% of the people living with HIV/AIDS in developing countries
have access to ARVs. Therefore more effective, better-adapted and simplified
treatments need to be developed.
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Interventions to prevent the spread of TB still lack the desired efficacy, yet Direct
Observed Treatment by Short regimes (DOTS) has shown how high cure rates and a
reduction in incidence, morbidity and mortality can be achieved. Although a total of
148 countries currently use the DOTS strategy, access is only offered to about 55%
of the world’s population. In several countries, nation-wide commitment to the
DOTS strategy has succeeded in reversing an increasing trend in the prevalence of
TB and putting the country on track to halving new cases or the incidence of TB
every 10 years.
Insecticide-treated nets and intermittent preventive treatments can significantly
reduce a large proportion of the burden of disease from malaria. Despite the fact that
more than five million insecticide-treated nets were distributed during 2000-2001,
the proportion of children under five in Africa sleeping under insecticide-treated nets
remains below 10%, and the average use of bednets is still only 1% of the African
populations at risk. It is only in Vietnam where the child mortality rate due to malaria
has declined over the last decade. In Sub-Saharan Africa the incidence of malaria has
increased. The rapid increase in drug resistance suggests that malaria deaths may be
poised to rise sharply. Progress on phasing out DDT for malaria control has been
made with the adoption of the Persistent Organic Pollutants (POPs) Convention in
Stockholm May 2001. Exemptions have been given to developing countries on the
condition that research for safe and alternative chemicals and non-chemicals would
continue in order to find an equally efficient and affordable tool for malaria
prevention.
A particularly important issue for HIV/AIDS is the current focus by the international
community on instability and insecurity whereby a series of measures, which are
not always built on the defence of fundamental human rights are being proposed
and taken further. The respect or non-respect for human and civil rights and the non-
discrimination or discrimination against people with HIV/AIDS are of increasing
concern in many countries but are not always sufficiently addressed. The debate goes
well beyond the right to health and includes non-discrimination in the workplace and
society, the right to inheritance, freedom of movement, and the right to marry.
Frequently, legislation discriminates against HIV-infected people.
2. Financial resources remain derisory. The CMH calculated that current actual
spending on health in the least developed countries4 (approximately USD 13 per
person per annum) need to be increased to at least USD 30-40 per person per annum.
This will require approximately USD 27 billion per annum in donor grants by 2007,
compared with the USD 6 billion per annum currently available, and an additional
budgetary outlay from developing countries of USD 23 billion by 2007. The CMH
also provided a detailed estimate of annual financial needs to cover HIV/AIDS,
malaria and TB, totalling USD 9.2 billion. This is a minimum estimate for
                                                
4 The Least Developed Countries are presently 49: Afghanistan, Angola, Bangladesh, Benin, Bhutan,
Burkina Faso, Burundi, Cambodia, Cape Verde, Central African republic, Chad, Comoros, Democratic
Republic of Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gambia, Guinea, Guinea Bissau,
Haiti, Kiribati, Lao People’s Democratic Republic, Lesotho, Liberia, Madagascar, Malawi, Maldives,
Mali, Mauritania, Mozambique, Myanmar, Nepal, Niger, Rwanda, Samoa, Sao Tome and Principe,
Senegal, Sierra Leone, Solomon Islands, Somalia, Sudan, Togo, Tuvalu, Uganda, United Republic of
Tanzania, Vanuatu, Yemen and Zambia (UNCTAD 2001 -
http://www.unctad.org/en/pub/ldcprofiles2001.en.htm).
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investments with immediately possible levels of delivery with an emphasis on
expanding the lower levels of district health systems, such as health posts and
outreach services. African countries have agreed to allocate 15% of their national
budgets to health (Abuja, April 2000). Some, such as Nigeria, are using debt relief
for substantial renewed investments in health, in particular HIV/AIDS. Countries
with a high disease-burden are demonstrating their commitment to TB control by
financing 60% of TB treatment budgets themselves. Nevertheless, considerable
resource mobilisation challenges remain - particularly for Africa, and most
particularly for HIV/AIDS. The Global Fund to Fight AIDS, TB and Malaria
(GFATM) aims at an additional outlay of USD 2.3 billion for 2003 and USD 4.6
billion for 2004; to date a total of USD 2.1 billion has been committed for the
forthcoming five years.
3. PROGRESS OF THE PFA TO DATE
The PfA was designed to link country-level actions aimed at increasing people’s access to
existing interventions, goods and services, with enabling global action on affordability and
investment in the development of specific global public goods. Three areas for action were
identified: impact, affordability and research. These areas for action are inter-related and
complementary. Implementation requires coherent, collective and simultaneous action.
3.1. Impact
3.1.1. Optimising the impact of Health, AIDS and Population interventions targeted at
major communicable diseases and poverty reduction
The ambitious target in the Programme for Action to increasingly prioritise in-country /
regional allocations for improved 'health' outcomes, in partnership with developing
countries and other partners, has so far brought relatively indistinct results. A longer time-
scale will be needed before real impact becomes clearly visible. 'Health' allocations are
traditionally and proportionally higher in the EC-funded programmes in Asia, Latin America
and the Mediterranean, than in the European Development Fund (EDF). A more coherent
focus on reaching the MDGs within the RELEX family is needed, especially for countries
where the HIV/AIDS epidemic is advancing rapidly (India and China). The establishment of
an EC Programme for Action Interservice Group (November 2002) is intended to take the
PfA forward across the Commission and in all developing countries.
1. At the end of 2001 Programming Guidelines for Health, AIDS and Population were
shared with Commission Delegations. All EC Country Strategy Papers/National
Indicative Programmes (except for the 'non-notified ACP countries') have been
finalised at the end of 20025. The current level of allocations for 'health as a focal
sector' programmed under the 9th EDF is 3.7% (€ 280 million). 22.3% from the
9th EDF (€ 1.6 billion) is programmed for 'macro-economic support with social
development conditionalities'. During 2002, regional and intra-ACP funds have been
programmed for 'health' in ACP countries from the 6th - 9th EDF (€ 104 million in
total: € 60 million for the GFATM from the 6th and 7th EDF and € 44 million for
reproductive health / malaria from the 8th and 9th EDF). Additional funding from the
                                                
5 Commission staff working paper: ‘Progress report on the implementation of the Common Framework
for Country Strategy Papers, SEC (2002) 1279, 26.11.2002. See Annex 2 for multi-annual financial
provisions.
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9th EDF intra-ACP regional funds and from 9th EDF reserves is currently being
discussed with the ACP countries. MEDA programming for ‘health’ for 2002-2004
represents 2%, Asia (2002-2004) is 14.1% and Latin America (2002-2006) 1.9%.
The current multi-annual provisions for all developing countries total € 423.2 million
for ‘health and population’, less than 3.3% of total EC development aid
programming. EU Member States - FI, DE, UK, B, FR, S and NL - have moved
towards a greater focus on the MDGs for health in their aid programming.
2. At the beginning of 2002, the Commission agreed with the European Parliament
Committee on Development to ensure that, for development spending from the EC
Budget, at least 35% will be allocated to 'social infrastructure'. This benchmark is an
indicator for health and population, education, water supply and sanitation and
government and civil society, following DAC sector category 1. The current multi-
annual provisions for all developing countries for ‘social infrastructure’ represents €
4.651 billion, i.e. 36.3% of total EC development aid programming.
3. During 2001 the Commission revisited 22 dormant 'health' programmes (ACP and
ALAMEDA) and de-committed or redirected funds where appropriate6. The reform
of the Commission’s External Relations services, helped speed up disbursement
levels substantially. In February 2001, the total ongoing Health, AIDS and
Population portfolio disbursement rate was set at 17% (i.e. disbursement versus
total commitments). This is set to date at 23% for the same portfolio (1995-2000).
Yet figures for 2001 and 2002 are more promising with, throughout the past two
years, a clear improvement in the overall budget execution performance, including an
increase of 20% in 2001 payments compared to 2000.7 The new information system
(CRIS) has been phased in during 2002 and is expected to be fully operational by
beginning 2003.
4. The European Community and its Member States are increasingly working towards
the harmonisation of policies and procedures to improve impact in-country. Joint
European Commission/European Union missions to a number of pilot countries
(Mozambique - Morocco - Vietnam - Nicaragua) were launched in September 2002
with the aim of assessing the potential for better harmonisation in the areas of health
and education. It is clear that closer donor co-ordination should be based on a step by
step approach, moving from joint consultation and information exchange to joint
situation analyses, programming and implementation structures, including an
effective information flow between HQ and delegations/embassies. The Commission
has established a Task Force to work on a detailed Harmonisation Action Plan for
health, HIV/AIDS and education. As a result, the current in-country work on the use
of specific indicators and on measuring progress towards the MDGs should be
improved.
                                                
6 While not all dormant 'health' projects have been closed, the mass of "dormant" funds against "active"
resources is 27% for health in general, 10.3% for HIV/STI related projects and 6.8% for programmes
targeting control of communicable diseases.
7 COM(2002) 490 final Annual Report 2001 on the EC Development policy and the Implementation of
the External Assistance, 12.09.2002.
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5. Throughout 2001 several resolutions on the Programme for Action were adopted: the
Council resolution on 14 May 2001; the EP resolution on 4 October 20018; the ACP-
EU Joint Parliamentary Assembly resolution on 1 November 2001. The
Commission’s proposal for a legal base for the EC contribution to the Global Fund to
fight AIDS, Tuberculosis and Malaria (GFATM) was adopted on 23 October 2001,
and on 19 December 2001 the Council and EP adopted the contribution by the EC to
the GFATM9.
6. The Commission has reformulated the regulation creating a special budget line (B7-
6311) for HIV/AIDS, malaria and TB, in line with the follow-up to the Programme
for Action.10 Throughout 2002 this regulation has been thoroughly discussed in
Council and Parliament.11 The Commission proposed an almost threefold increase in
allocations (from € 25.27 to € 73.35 million). It is expected that the regulation will be
adopted by the EP and Council beginning 2003.
7. In March 2002 the Commission adopted a Communication on Health and Poverty12
and a subsequent Council resolution was adopted on 30 May 2002. Council’s
resolution referred to increasing the volume and improving the delivery of aid. It
stated: […] in view of reaching better health outcomes and attaining the
internationally agreed health development goals, the EU will strongly support those
developing countries who agreed to work towards the targets set by themselves for
investments in health, such as in Abuja (15% of national budgets) […] and […] In
this context, the Council recalls its conclusions on the UN Conference on Financing
for Development in Monterrey, agreed by Foreign Ministers on 14 March and
endorsed by the European Council in Barcelona whereby the Member States
collectively commit themselves, as a first significant step, to increasing their overall
ODA volume in the next four years. A substantial share of that increase should go
to support for social development in developing countries with special emphasis on
improving health and education outcomes. […] Discussions in the European
Parliament on the Health and Poverty Communication started in October 2002 and
remain in progress.
8. At the OECD/DAC in 2001 the Commission declared its determination to increase
the participation of contractors from developing countries in the execution of
Community development programmes and projects through an initiative in favour of
the increased untying of Community aid. The Commission proposed to use
                                                
8 On 15 March 2001 a European Parliament Resolution on access to drugs for HIV/AIDS victims in
developing countries noted the inclusion of a commitment to tiered pricing in the Commission’s
Programme for Action and called for a system allowing developing countries equitable access to
medicines and vaccines at affordable prices.
9 Decision No 36/2002/EC of the European Parliament and of the Council of 19 December 2001
concerning the Community contribution to the Global Fund to fight HIV/AIDS, tuberculosis and
malaria, Official Journal L 007 , 11/01/2002 P. 0001 - 0002.
10 Proposal for a Regulation of the European Parliament and of the Council On aid for poverty diseases
(HIV/AIDS, malaria and tuberculosis) in developing countries. COM/2002/0109 final -
COD 2002/0051.
11 In parallel, the Commission proposed the revision of the regulation for the special budget line
(B7-6312) on 'aid to population programmes' to include 'reproductive and sexual health and rights'.
12 COM(2002) 129 final, 22.03.2002. This Communication details the relationship between health and
poverty. It outlines critical elements of a coherent development approach to improve health and well-
being and establishes, for the first time, a single Community policy framework to guide investment in
health, AIDS, and population within the context of overall European assistance to developing countries.
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medicines and supplies/products for HIV/AIDS, malaria and TB as a pilot exercise.
The first EC dossier to benefit from untying was an international tender in
Zimbabwe. On 18 November 2002, the Commission adopted a Communication on
untying of aid, which further clarifies the approach taken by the Community in light
of the OECD/DAC decision related to aid untying.
3.1.2. Strengthening of pharmaceutical policies and capacity building
1. The strengthening of pharmaceutical policies has been substantially reinforced for
ACP countries. The EC programmed, through a partnership with the WHO, € 25
million (9th EDF) for regional co-operation and capacity building including
enhanced and improved essential drug policy and regulatory schemes. The financing
proposal has been discussed at the EDF Committee in November 2002 yet adoption
will only take place once the 9th EDF is formally ratified. Additional efforts are
ongoing to develop and finance a broader strategic partnership13 with the WHO.
2. In April 2002, the WHO Expert Committee on essential drugs decided on the 12th
WHO Model List of Essential Medicines (the first having been adopted in 1977). It
contains 325 medicines, including 12 ARVs14 for the treatment of HIV. Along with
the model list, the WHO released guidelines on scaling up ARV treatment. The
action is seen as a breakthrough in a comprehensive "prevention through care"
package that could contribute to wider access to treatment over the coming years.
3. Discussions are under way between the Commission and ACP countries, Roll Back
Malaria, Médicins Sans Frontières and other partners relating to existing malaria
national protocols. There is a need for a change of protocols to include artemisine
combination therapies, especially in East Africa15.
3.1.3. Developing local manufacturing capacity
1. It is becoming apparent that there is an emerging need to consider global
manufacturing capacity for many essential medicines and pharmaceutical starting
materials. If the scale of the epidemics continues to grow, it is not impossible that the
current capacity of pharmaceutical production will be insufficient. There are finite
amounts of raw materials for some ARVs, for example, due to the limited numbers
of manufacturers. The Commission will examine the extent of such production
capacity constraints as tiered pricing and public tendering increase, affordability is
promoted and demand rises.
2. Several initiatives for the development of local production capacity are in progress.
One, for example, is for the local production of condoms in South Africa, linked with
social marketing. The European Investment Bank (EIB) is taking this analysis
forward and is considering financial support. The EC is also exploring other partners
                                                
13 A Strategic Partnership could include: involvement of EC in governing, statutory and political bodies of
the selected partner; contribution to policy debates; financial cooperation in operational activities;
financial support for core capacities (15.7.2002 DG DEV A/2 note to Joint Management Meeting).
14 They include nevirapine and zidovudine - previously listed for prevention of mother-to-child
transmission but now also recommended for treatment of HIV in adults and children. The new
medicines in the EML are abacavir, didanosine, efavirenz, indinavir, lamivudine, lopinavir, nelfinavir,
ritonavir (low-dose), saquinavir, and stavudine.
15 The new EML includes Artemether-lumefantrine (Co-artem) as a combination artemesin product.
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in priority areas for technology transfer and local production of pharmaceuticals, for
instance anti-retrovirals, artesunate and an oral polio vaccine.
3. The transfer of high volume production capacity to poor countries as well as
building up of R&D capacity, is an important part of a strategy to create sustainable
access to medicines. These developments must run in parallel as no technology can
be mastered without significant adaptations and increasing local technical
competence. Moreover, it will not necessarily disadvantage Europe’s pharmaceutical
industry. For some products, freeing production capacity for what may be more
profitable production may create a win-win situation. However, in some cases, such
as vaccines, it is important that manufacturing capacity be developed well before the
lowering of production in OECD markets. There is now a real shortage of some low-
profit traditional vaccines, such as the oral polio vaccine and the yellow fever
vaccine, as producers in developed countries have tended to focus production
capacity on more profitable – and expensive – vaccines.16
3.2. Affordability
3.2.1. Tiered Pricing
1. Europe’s advocacy of the tiered pricing concept has been successfully pursued.
The PfA, the May 2002 Council Conclusions and the EP Resolutions on the subject,
all include clear references to the need to introduce tiered pricing as the norm for key
pharmaceuticals destined for the poorest developing countries, while at the same
time seeking to prevent imports of the tiered priced products to the EU market.
Discussions on taking the tiered pricing agenda further forward, along with other PfA
actions, have taken place with the Member States and with civil society. Tiered
pricing is also consistently addressed by the EC in discussions relating to the
procurement of goods and services funded by the GFATM. There is, in general,
broad consensus in favour of tiered pricing and support for the mechanism is on the
increase in Europe. Yet discussions with the US have, so far, only gradually led to
tangible results.17
2. On 30 October 2002 the Commission adopted a proposal for a Council Regulation
to avoid trade diversion into the European Union of certain key medicines
originally destined for the poorest developing countries and sold at very reduced
prices18. This regulation provides for increased protection against import to the EU of
pharmaceutical products which have been sold to least developed and low income
developing countries at prices reduced by at least 80% compared to OECD average
ex-factory price or, alternatively, sold at direct manufacturing cost plus a maximum
of 10%. The draft regulation is a novelty as it aims at protecting both products
covered by intellectual property rights and non IP-protected goods and is also
identifying a target to be achieved in price reduction. In practise producers and
exporters are invited to notify to the Commission the products for which they wish
the additional protection offered. The list will, together with appropriate
                                                
16 See WHO, UNICEF, The World Bank, State of the World’s Vaccines and Immunisation, November
2002.
17 During the GFATM Board Meeting in October 2002 the US agreed to use tiered pricing as a
mechanism for GFATM procurement.
18 Proposal for a Council Regulation to avoid trade diversion into the European Union of certain key
medicines, COM/2002/0592 final - ACC 2002/0257
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identification in the form of a mandatory logo and possibly additional voluntary
differentiation, enable the customs authorities to suspend the release of suspected
tiered priced products at the borders of the EU market. Industry participation in the
scheme is entirely voluntary. The draft regulation invites also non-European
producers to notify their products. The regulation will hopefully serve as a model for
other developed countries to follow. The more pharmaceutical products are
submitted for approval under the regulation, the more likely it is that other countries,
including the US, will become receptive to the idea of definitively preventing the
flow of low-priced medicines back to their market.
3.2.2. Tariffs and taxes
The Commission commissioned a study on tariffs and other duties paid when pharmaceuticals
are imported into developing countries. Preliminary results show great differences in the
application of tariffs, other duties and fees. Customs duties vary from 0% to 35% for
compounds as well as for medicines and vaccines in the 57 countries reviewed. It is clear that
populations in a number of developing countries which apply high rates, would benefit from
cuts. In the Doha tariff negotiations on non-agricultural goods, the need to improve the
situation on tariff cuts for pharmaceuticals could be addressed.
3.2.3. Intellectual Property Protection
1. Throughout 2001 and 2002 the EC and other WTO Members advanced substantially
on discussions relating to intellectual property rights (IPRs) and public health.
These efforts were most apparent in the results of the negotiations in Doha, by the
adoption of the Doha Declaration on TRIPs and Public Health. The Declaration
usefully clarifies the rights, obligations and flexibility available under the TRIPs
Agreement. In addition it allows LDCs to defer implementation of patent law with
respect to pharmaceuticals until 1 January 2016. Presently, discussions take place in
the TRIPs Council relating to paragraph 6 of the Doha Declaration. In March 2002
the EC presented a position paper discussing two possible 'expeditious solutions' to
the difficulties faced by WTO Members with insufficient or no manufacturing
capacities with regard to making effective use of compulsory licensing provided for
under the TRIPs Agreement. The EC approach is that article 31(f) should be
amended to include a clearly circumscribed exception to the export restriction
imposed by the same article. Outstanding issues were expected to be resolved before
the end of 2002,but this deadline could not be met because of the US refusal to
endorse a draft decision on which all other WTO Members had agreed. In order to
break this deadlock, the EU tabled a compromise proposal on 7 January 2003. As a
result, discussion resumed in Geneva.
2. The Commission is also developing a work plan for reinforced technical assistance
in the areas of trade and development, which includes support to the efforts of
developing countries to participate in trade negotiations, support to building
developing countries' capacity to implement trade agreements and support for the
necessary policy reforms and investments19. Several countries, such as Mauritius,
requested specific studies on IP and a general study on TRIPs implementation in
Sub-Saharan Africa is being contracted. Less progress has been made on work with
the World Intellectual Property Organisation (WIPO), but partnerships with key
                                                
19 Trade and Development Communication COM (2002) 513 final.
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civil society groups, such as Oxfam and MSF, and with the pharmaceutical industry
(in particular with regard to tiered pricing) have been further developed.
3. Some Member States, in particular the UK and NL, organised special fora to discuss
Access to Medicines and IP issues. In November 2002, the UK High Level
Working Group on Access to Medicines, in which the Commission took part,
presented a set of recommendations to support specific action on the R&D agenda,
and to facilitate a voluntary system of widespread tiered pricing as the operational
norm.20
3.2.4. Corporate Social Responsibility (CSR)
The area of Corporate Social Responsibility (CSR) was not specifically highlighted in the
PfA yet its rising importance has been an opportunity to further the PfA’s overall objectives.
In September 2002 the Commission launched an implementation strategy with respect to CSR
following the July adoption of a specific Communication21 and laying the basis for a special
CSR Stakeholder Forum, established on 16 October 2002. Different corporations and NGOs
are planning to participate actively in the specific Round Table (scheduled for 2003) on "CSR
and Development" which will promote the international dimension of CSR, and during which
thematic areas such as health, HIV/AIDS (developing sound workplace policies and private
sector advocacy responsibilities), education, gender and core labour standards will be
examined. It is often argued that corporate businesses are not empowered by shareholders to
make substantial financial contributions to development, yet many are increasingly concerned
about developing or preserving their reputations through being developmentally responsible.
A number of examples of businesses becoming involved in providing for HIV infected
employees are now emerging and more efforts will need to be undertaken to further
encourage the corporate sector (not just the pharmaceutical industry) and shareholders to
become socially involved, acknowledge their responsibility for achieving the MDGs and
participate in the international development agenda. In this context, the provision of malaria
and TB treatment to workers by businesses in the agricultural and mining sectors are being
explored as well.
3.3. Research and Development
With the Programme for Action, the European Community agreed to support new approaches
that will stimulate the development of specific global public goods targeting HIV/AIDS,
malaria and TB. The support will be given through direct as well as indirect incentives by
providing much higher levels of public funding for Research and Science & Technology
(S&T) capacity building.
3.3.1. Strengthening of research in poverty related diseases
1. The Fifth Framework Programme for Research, Technological Development and
Demonstration Activities (FP5, 1998-2002) allocated more than € 109 million to
research on HIV/AIDS, malaria and TB. More than 77 research projects were
funded, under the Quality of Life Programme (QoL) or the International Cooperation
(INCO) Programme. 32 of the projects were on HIV/AIDS (with a budget of around
                                                
20 Report to the Prime Minister, High Level UK Working Group on 'Increasing access to essential
medicines in the developing world, policy recommendations and strategy'. Clare Short, Secretary of
State for International Development, 28 November 2002
21 Corporate social Responsibility: a business contribution to Sustainable Development, COM (2002) 347.
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€ 49 million), 24 on malaria (€ 29 million) and 21 on tuberculosis (€ 30 million).
Research includes methods to increase DOTS uptake and the long-term validity of
ITN use. The research projects were implemented in partnerships between research
institutions from EU Member States, Associated Countries, countries in Africa, Latin
America, and Asia, and the USA. Projects funded under the QoL Programme aimed
to develop new vaccine candidates and new lead substances. Impressive scientific
results have been achieved by some of the projects, giving hope that new preventive
and/or therapeutic interventions against HIV/AIDS, malaria and tuberculosis can be
developed.
2. Poverty related diseases have become one of the priorities of the Sixth Framework
Programme of Research, Technological Development and Demonstration Activities
(FP6, 2002-2006). FP6 was adopted in July 2002 and a substantial budget increase of
€ 400 million has been allocated to HIV/AIDS, malaria and TB research. The overall
research strategy for R&D in FP6 is built on two components:
i) the support for large research consortia which integrate different disciplines and
approaches and which generate new partnerships between the different players
involved. Different phases of the R&D development process from discovery to safety
testing in humans shall be covered. Roughly € 200 million are earmarked for such
activities.
ii) the establishment of a clinical trials programme to unite and support Europe’s
clinical trial activities specifically targeted at interventions for use in developing
countries (EDCTP). The Commission earmarked € 200 million for this initiative.
3.3.2. European and Developing Countries Clinical Trials Partnership (EDCTP)
The overall goal of the EDCTP is to accelerate the development and evaluation of new
vaccines, drugs, and other preventive or therapeutic tools against HIV/AIDS, malaria
and TB. Discussions in the European Parliament and Council are currently ongoing to use for
the first time Article 169 of the Treaty to establish and implement the EDCTP22. The EDCTP
has three major objectives:
1) networking and co-operation between national programmes to ensure their efficiency
and impact;
2) acceleration of the development of new products by supporting clinical trials in
developing countries;
3) strengthening clinical research capacities in developing countries.
The EDCTP will have a target budget of € 600 million. One third of the budget will be
contributed by the Community, whereas another € 200 million will be provided by Member
States and Norway with an additional € 200 million expected from the private sector, R&D
industry, foundations and charities, and Community development funds (EDF or special
budget line).
                                                
22 Article 169 enables the Community to participate in research programmes undertaken jointly by several
Member States, thereby creating incentives for co-operation of national activities and creating added
value and critical mass at the European and Developing Countries level.
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The EDCTP is expected to be operational during the second half of 2003. In line with the
Doha declaration, the developing countries should have access to the products developed by
the EDCTP. A carefully balanced management structure ensures that the developing countries
are important stakeholders and equal partners in strategic decisions. In line with this, African
partners will both participate in prioritising new interventions and in the development of
strategic clinical trials action plans.
3.3.3. Capacity building for R&D in developing countries
1. Clinical testing and introduction of new drugs and vaccines in developing countries
require training of national health workers. Within the EDCTP budget € 150
million is therefore earmarked for capacity building in developing countries.
Activities include support to South-South, North-South networking and co-operation,
technology transfer, strengthening and upgrading of facilities and services at research
institutes and clinical institutes in developing countries. To ensure sustainability,
mechanisms have shall be developed for retention of well-trained and qualified staff
in Africa.
2. Most importantly, support for capacity building in clinical trials shall be linked with
more general support measures for infrastructures in developing countries.
Mechanisms still have to be developed to ensure this. The prioritisation of health
investments by the countries concerned is one important component. Continued
efforts to support infrastructures and investments through institutional capacity
building in developing countries are essential in this regard.
3.3.4. Indirect incentives to increase R&D investments of private sector in specific Global
Public Goods
1. The EC intends to increase the overall R&D expenditure in the EU up to 3% of
GDP.23 To achieve this, the EC will particularly explore various initiatives to
stimulate investments by the private sector. Indirect incentives to increase the
private sector’s research in HIV/AIDS, malaria and TB have so far focused on ways
to facilitate market access and increase profitability. In line with this, the
introduction of a special regulatory procedure to obtain a marketing authorisation for
poverty-related products shall be further explored.
2. Such an approach has been successfully used for rare (so-called orphan) diseases.
The expectation that the EU orphan drug regulation24 would also stimulate the
development of medicines for poverty-related diseases (which falls below the
prevalence thresholds in Europe set by the orphan drug regulation, such as malaria),
has not as yet been fulfilled and was neither the regulation’s prime objective. Yet, -
other- specific legislative instruments to encourage the clinical development of
new therapies for poverty-related diseases will therefore have to be re-examined or
further explored. This could include specific provisions for fast track approval, and
extended marketing authorisation exclusivity. Next to other indirect subsidies for
research, product development and testing - such as corporate taxation - the
extension of patent protection and / or the transfer of patent rights were identified in
the PfA as an alternative way forward and shall be further explored. Scientific advice
                                                
23 COM(2002) 499 final, 11.09.2002.
24 EU Regulation on Orphan Medicinal Products COM 141/2000.
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to develop medicines for resource poor settings, and advice leading to GMP/GCP
certification shall be considered. As a first step, the EC has revised its
pharmaceutical regulation to allow CPMP, the body giving scientific evidence to
EMEA, to provide scientific advice on medicinal products destined for exclusive use
in third countries.
3. In June 2002 the EC AIDS Vaccine Task Force reviewed preliminary results of the
World Bank studies on ability and willingness to pay for a vaccine. Following this
meeting contacts have been reinforced with the South African AIDS Vaccine
Initiative (SAAVI) and the International AIDS Vaccine Initiative (IAVI). The
Commission has also committed an additional € 1.35 million to the Medical
Research Council in South Africa in order to consolidate lessons learned and
intensify an ongoing EC-funded vaccine preparedness programme, providing the
required enabling environment for expanded HIV vaccine development activities in
South Africa. The Commission is part of the IAVI policy advisory board and the
country preparedness advisory group of the International Partnership for
Microbicides.
4. The during the past two years the Commission has discussed several ways of
increasing and enhancing partnerships with existing global alliances directly or
indirectly linked to the three major communicable diseases. In May 2002 discussions
were held with the Global Alliance for Vaccines and Immunisation (GAVI).
GAVI works towards having 80% of the poorest countries with adequate delivery
systems capable of introducing hepatitis B vaccine by 2002 and by 2005 having at
least 80% coverage with routine immunisation in all districts. The Commission is
considering how to assist countries develop plans to sustain GAVI-funded
vaccination programmes after their five-year grant ends (inter alia through linkages
with budget support for poverty reduction strategies that include immunisation
coverage as an indicator). GAVI is considered an important partner in consolidating
efforts to prepare the ground for a future AIDS vaccine. The Commission will also
need to consider how best to encourage further private sector participation.
3.4. Participation in Global Partnerships: Policy and Political Dialogue
1. Throughout 2001 and 2002 the European Community and its Member States have
been proactive in addressing the specific issues addressed by the Programme for
Action in global fora such as G825 Summits, the EU/US Summits in Queluz,
Washington and Gothenburg, the EU/Canada and EU/Japan Summits in 2001, the
follow-up to the Cairo Plan of Action within the EU/OAU forum (leading to the
EU/AU Summit in Lisbon in 2003), the LDCIII Conference in Brussels in 2001, the
UNGASS on HIV/AIDS in 2001, the Barcelona AIDS Conference in 2002, and the
Doha WTO Ministerial, the Monterrey Conference and the Johannesburg Summit.
2. At the Barcelona European Council (and the Monterrey Conference) the EU
Member States agreed to increase their ODA in order to approach the 0.7%
ODA/GNI UN target by raising average contributions from 0.33% to 0.39% by 2006.
Together with the EU Member States Health and Education Experts the Commission
                                                
25 The EC / G8 EU Member States consensus was clearly demonstrated during the negotiations leading to
the G8 Summits in Okinawa (2000), Genoa (2001), Kananaskis (2002) and now preparing for Evian
(2003), with the Okinawa Communiqué presenting the most comprehensive global approach to tackling
the three diseases.
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will further develop a framework for the increased ODA focused on social
development with an emphasis on improved health and education outcomes.
3. From the outset the Commission has been an active partner in the establishment and
operation of the Global Fund to fight HIV/AIDS, TB and Malaria (GFATM).
After having participated in a series of informal meetings to establish the GFATM,
the EC hosted a stakeholders forum in Brussels (in July 2001). This led to the
establishment of a transitional working group (TWG) and a technical support
secretariat (TSS). The final TWG meeting took place on 13-14 December 2001 and
the first Board Meeting, on 28-29 January 2002, marking the official hand-over from
the TWG to the Board of the Global Fund. The Commission, in a constituency
including Belgium and Austria, holds a seat on the Board26. So far the European
Community has contributed € 120 million (€ 60 million from the 6th and 7th EDF
and € 60 million from the EC Budget). In view of the need to boost the EU
contribution to the Fund, the Commission is currently examining the scope for
additional future contributions from both the EC budget and the EDF (reserves).
At the GFATM Board Meetings (three so far) the EC has insisted on upholding the
previously agreed principles for the GFATM, including a) the Fund is a financing
mechanism and should not become a UN body or new international institution; b) the
structure should remain 'lean and mean' with no new entities established in country;
c) the interests of developing countries are the key determinants for decisions and the
poverty focus is non-negotiable; d) decisions should be made transparently and on
merit rather than through political lobbying and should be based on high-quality
proposals; e) the Fund should deliver improved health outcomes while fully taking
into account national frameworks and ownership, and building on existing
mechanisms - i.e. the Fund is not a ‘vertical’ instrument; f) monitoring and
evaluation indicators and criteria must be well defined and programme and financial
accountability clarified before the first disbursements are made. Other specific
agenda items agreed in the Programme for Action and taken forward in the GFATM
are: working in innovative ways with the private sector through new partnerships,
increasing financial resources, poverty focus, price transparency and tiered pricing,
the consistent reference to the TRIPs flexibility instruments reinforced by the Doha
Declaration, preference for locally produced products, discouragement of in-kind
medical donations.
In-country the GFATM works through Country Co-ordinating Mechanisms (CCM)
which incorporate all relevant stakeholders. The set up and functioning of CCMs are
unique and have great potential for working in true partnership at country level. At
the October 2002 Board meeting consensus was reached on policy principles for
procurement and supply management, with the US and the private sector agreeing to
tiered pricing, price transparency and restrictions on in-kind donations, in line with
the EC/EU position. The Fourth Board meeting will be held at the end of January
2003, and the Fifth is to coincide with the Evian G8 Summit.
One of the biggest challenges the Fund will face is in maintaining its momentum.
There is also an ongoing need for close co-ordination among EU participants in the
Fund, currently spread among several different “constituencies” represented on the
                                                
26 For more information about the GFATM and EC contribution see the EC DEV/RELEX/AIDCO and
DELEGATIONS STAFF BRIEFING NOTE - September 2002.
22
Board. The need for co-ordination is likely to increase over time rather than
diminish.
4. Over the past two years a series of activities has been undertaken to foster stronger
partnerships with EU Member States, civil society and the private sector, UN
agencies, funds and programmes, the World Bank and the EIB. Discussions started
with the latter on local condom production in Africa. The World Bank is a strong
partner in different global fora for capacity building and specific activities such as
research into willingness to pay for a vaccine and community preparedness for an
AIDS vaccine. Work with UNAIDS and the WHO has been reinforced at different
levels and in different fora, with the shared key priority for forthcoming years of
better partnership at the country level. Dialogue with civil society has been
institutionalised through the ‘trade and public health’ debate but is, as yet, less strong
in the other areas of the Programme for Action. Pharmaceutical companies are
increasingly involved as partners in policy and implementation, in particular in areas
such as tiered pricing and research and development. Other private sector partners
are also increasingly committed and ready to work with the EC/EU on fighting
communicable diseases in developing countries. Partnerships with the developing
countries (in particular the LDCs and the LICs) are likely to grow in significance,
once these are brought together in a Stakeholder Forum on Communicable Diseases
in the Context of Poverty Reduction which the Commission intends to establish.
4. MONITORING AND EVALUATION
The PfA stipulated that appropriate mechanisms, resources and partnerships will be put in
place to monitor implementation and to participate in a global monitoring system
encompassing the efforts of all international partners. Efforts are being made by a number
of international partners, including EU Member States and the EC, to agree on impact and
high-level outcome indicators as part of a joint pro-poor, global and gender- sensitive
monitoring system to assess progress towards the MDGs. These efforts must be consistent and
complement the Commission’s efforts to strengthen country ownership and national statistical
capacity to monitor pro-poor health outcomes and health systems performance.
1. Coherence with the PRSP process and country programming. The shift of EC
co-operation towards macro-economic support linked to social sector outcomes and
sector-wide approaches has led to increased efforts towards consistency in country
programming. The work on sectoral indicators is co-ordinated with the development
of overall Development Indicators in the context of PRSPs and macro-economic
support27. The intention is for the 2003 EC Annual Report to include reporting on the
MDGs based on a limited number of indicators (12 impact/outcome and output)
drawn from the list of 48 indicators associated with the MDGs. Countries that have
opted for a sector-wide approach in health have developed a set of about 20 sector-
wide indicators. In Ghana for example, the Commission has directly supported the
process of selection and application of these indicators through its own Technical
Assistance28. More efforts are under way to measure pro-poor health sector
performance and to disaggregate data by social sector, gender and regions.
                                                
27 DG DEV 2002, Guidelines for the use of indicators in country performance assessment.
28 Accorsi, S. 2002, Measuring Health Sector Performance through indicators: towards evidence-based
policy. A review of the experience monitoring in the framework of sector-wide approach in Ghana.
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2. OECD/DAC. The Commission is, as are most EU Member States, taking active part
in the DAC Network on Poverty Reduction / Subgroup on Poverty and Health and
contributed a sub-chapter on Monitoring and Evaluation to the Draft Guidelines on
Poverty and Health drafted by the Subgroup. The Guidelines have formulated a set of
key principles for monitoring health systems performance towards pro-poor health
outcomes.29
3. Partnerships with DfID, the WHO, the World Bank, the private sector and civil
society. The Commission and other EU Member States have joined a DfID-led
working programme for monitoring health systems performance and pro-poor health
outcomes. Others taking part in this joint programme (2003-2009) are the WHO, the
World Bank, USAID, the Rockefeller Foundation and others. The aim of the
programme is to improve the capacity to measure poverty and health, to monitor
health system performance, and to evaluate PRS and health sector reforms in
achieving pro-poor health outcomes. The programme will run, on demand, in
8-12 selected countries in Africa, Asia, Latin America and transition countries.
Country-led processes are expected to allow a sector- wide approach in co-ordinating
external support for performance and outcome monitoring and statistical capacity
building30. The private sector and civil society could be significant interlocutors and
partners in monitoring and evaluation.
4. GFTAM. Within the Global Fund, the Commission and EU Member States have
supported the Monitoring, Evaluation and results-based disbursement working
Group. Here the attempt is being made to apply results-based disbursement to a
range of indicators that has to respond to a variety of proposals financed by the
GFTAM. Proposed indicators are output, process and outcome indicators, ranging
from the improvement of reproductive health knowledge in school settings to actual
HIV prevalence rates.31
5. CONCLUSIONS
1. Two years after its inception the Programme for Action remains a comprehensive,
forward-looking and coherent EU policy framework making a significant
contribution towards improved country, regional and global action against the three
major communicable diseases. The PfA is strongly supported by Council and
Parliament, as well as by civil society and the private sector.
2. The case for targeting these three diseases remains valid and has even become clearer
than before with respect to HIV/AIDS. It remains the case that general opinion is not
yet fully mobilised around a clear sense of the global crises that these three diseases
constitute, and there is still an urgent need for large-scale collective action. The
European Community and its Member States are committed to keep the momentum
going in the fight against the three diseases as demonstrated above, particularly by
                                                
29 DAC & Subgroup on Poverty and Health 2002 draft Guidelines on Poverty and Health, 4 October
2002.
30 DfID, M. 2002, Final draft for consultation on a programme of work: "Measuring, monitoring, and
evaluating health systems performance to achieve pro-poor health outcomes".
31 GFATM 2002, Report of the Monitoring, Evaluation and Results-based disbursement Working Group -
October 2002.
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the vast scale of parallel and, in the case of the EDCTP, joint EC-MS actions at the
EU level presented in this report.
3. Many global public goods will not be achieved through domestic policy action alone
and depend fundamentally on concerted international action including significant
increase on R&D activities. The mobilisation of resources from national health and
other sectoral budgets and from the private sector will increasingly be necessary to
ensure full and reliable funding for global health concerns. GPG policy needs to be
further developed to ensure co-operation and equitable burden sharing in this
respect.
4. A number of actions spelled out in the PfA has been taken forward at the country,
EU and global level. Where progress has been less visible, this was either due to a
lack of appropriate resources within the Commission and/or within the Member
States, in particular in-country resources, to take forward large-scale programmes in
areas such as local manufacturing capacity, technology transfer, social marketing
partnerships with civil society, innovative research and development and working
through true partnerships in particular with the developing countries concerned.
Outstanding areas will be further addressed mainly but not exclusively through
the use of the EC poverty diseases budget line (2003 to 2006). All PfA actions are
directly or indirectly linked to other Community policies and actions working on
improved health, AIDS and population outcomes in developing countries.
5. The increase in ODA towards 0.7% ODA/GNI UN target by 2007 raises the need for
an EU framework for increased ODA focused on social development with an
emphasis on improved health and education outcomes.
6. A strong EU/EC voice is clearly key with respect to each area of action – impact,
affordability and research, and at global, EU and country level. EU positions on
targeted HIV/AIDS, malaria and TB actions have been significantly strengthened at
the global level, jointly with other partners, as a result of the PfA. Nevertheless, more
efforts are needed to provide regular and structured consultation with developing
countries at all levels.
7. One way such consultation will be further developed is through the creation of a
Stakeholders Forum on Communicable Diseases in the Context of Poverty
Reduction. It is intended that this forum will bring together Commission and EU
Member State officials, representatives of developing countries, NGOs, industry and
others.
8. In addition, civil society partners have an increasingly strong voice in policy
debates within all EU institutions, as well as nationally and globally. Implementation
of the PfA is subject to increasing monitoring by civil society and organisations and
business interests. The same bodies are highly active members on the Board of the
GFATM. It is important for this reason also, therefore, to strengthen existing
partnerships with all stakeholders involved, and to develop new partnerships where
necessary.
9. For the EC, successful partnerships require greater flexibility - to lead on some
issues where there is a genuine institutional gap, but to devolve responsibility for
other issues where the EC does not have a clear competence or is unable to bring
added value. The degree of formality in these partnerships should vary, with some
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partnerships requiring very precise joint agreements while others can rely on much
more informal understandings and working arrangements.
10. The Global Fund to fight HIV/AIDS, TB and malaria is one of the PfA actions to
have produced clear results in terms of resource mobilisation and innovative
approaches. Policy areas, which had previously not been successfully addressed in
other fora, are being addressed here. The developing countries have a strong voice in
the GFATM Board and the Fund’s overall governance arrangements. Important
topics such as tiered pricing and the strengthening of local manufacturing
capacities are also being addressed here. These cannot, however, be dealt with in the
GFATM alone. Renewed efforts are needed to work jointly at the European level as
well as with specific partners, in particular the US, on these issues. The next G8
Summit in Evian will provide a possible forum for taking forward the
Communicable Diseases agenda as reflected in the PfA as a follow up from what
was adopted by the G8 in Okinawa in 2000.
11. The Commission’s advocacy of tiered pricing for pharmaceuticals has clearly yielded
tangible results, culminating in the Commission’s October 2002 proposal for a
Council Regulation to avoid trade diversion into the European Union of certain
key medicines originally destined for the poorest developing countries and sold
at greatly reduced prices. Once adopted by Council, the Regulation should provide
a real protection for exporters, which in turn should develop from increased sales and
offers of low priced products to a larger number of countries. As exporters benefit
from the added protection there shall be pressure made on other developed countries,
including the US, to provide for similar measures. As the draft Council Regulation
includes reporting of volumes sold at tiered prices, these data will be useful to
improve access to data about the volumes of medicines distributed in the poorest
countries.
12. The paucity of information about pharmaceutical prices and production capacity is an
impediment to the development of robust pro-poor policies. Price transparency
(ensuring that production costs of producers are kept strictly confidential for reasons
of fair competition) will become increasingly important as developing countries
increase their procurement of key medicines within or outside the context of, for
instance, the GFATM. It is unsatisfactory for public authorities to have to piece
together price information about life-saving medicines from the fragmentary data
collected by NGOs or provided by just one or two companies, especially since price
remains an important determinant of access, and therefore life, for millions of people.
The Commission will study what measures should be introduced to improve
access to information about pharmaceutical prices. The same goes for
information about pharmaceutical manufacturing capacity, especially with
respect to pharmaceutical raw materials.
13. The EDCTP is a unique opportunity to create a long-term, sustainable and genuine
partnership between the EU and developing countries, which is essential to
accelerate the development of new products to fight the three diseases.
14. Nevertheless, additional efforts are needed in the area of the research and
development of new specific Global Public Goods, through the kind of
partnerships described above (public/private – EU/developing countries) and new
proposals for incentives and financing mechanisms. Increased attention should
now be devoted to this area of policy, which will probably prove of particular
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importance over the long term. The Commission will focus on developing proposals
to incentivise R&D for diseases which are currently neglected or where R&D is
lacking. Such proposals will include further examination of a number of ideas:
venture capital, low-cost loans, tax credits, guaranteed markets and the extension of
patent rights and/or market exclusivity including through the relationship which
might be established between different products.
15. In addition, the Commission will consider the need for a specific legislative
instrument to incentivise R&D for neglected and poverty diseases, along the lines
of the EU Orphan Drug Regulation. The Orphan Drug Regulation has been a success,
with a large number of applications now having been submitted to the EMEA for the
authorisation of such medicines. The Commission will explore whether the
environment for R&D into neglected diseases can be transformed in a similar way.
16. A final key challenge remains implementation and impact at country level. A series
of actions related to the ‘harmonisation of EU/EC policies and procedures’ has
started and will be further developed into specific action plans on a country-by-
country basis.
The support of the European and International community will only be effective where
countries themselves show a strong political commitment and have demonstrably ascribed
high priority to public health policies, prevention, care and treatment.
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Annex 1 :Acronyms
ACP Africa, Caribbean and Pacific
AIDS Acquired Immune Deficiency Syndrome
ALA Asia and Latin America development cooperation programme
ARIVA Appui Régional a l'Indépendance Vaccinale en Afrique
CMH Commission on Macro-economics and Health
CPMP Committee for Proprietary Medicinal Products (EMEA)
CRIS Common Relex Information System
CSP Country Strategy Paper
CSR Corporate Social Responsibility
DAC Development Assistance Committee
DDA Doha Development Agenda
DfID Department for International Development (UK)
DG Directorate General
EBAS EU-ACP Business Assistance Scheme
EC European Community
ECHO European Community Humanitarian Aid Office
EDCTP European Development Clinical Trials Partnership
EDF European Development Fund
ED/M/L Essential Drugs/Medicines List
EIB European Investment Bank
EMEA European Agency for the Evaluation of Medicinal Products
ESIP EU SADC Investment Promotion Programme
EU European Union
FP Framework Programme
G8 Group of G7 most industrialised countries and Russia
GAVI Global Alliance for Vaccines and Immunisation
GCP Good Certification Practice
GFATM Global Fund to fight AIDS, Tuberculosis and Malaria
GMP Good Manufacturing Practice
GPG Global Public Good
HAP Health, AIDS and Population
HIV Human Immune Deficiency Virus
IAVI International AIDS Vaccine Initiative
ITN Insecticide-treated nets
LDC Least Developed Country
LIC Low Income Country
MEDA Mediterranean countries development cooperation programme
NGO Non-governmental Organisation
NIP National Indicative Programme
OECD Organisation for Economic Cooperation and Development
PfA EC Programme for Action on Communicable Diseases in the Context of Poverty
Reduction
PRSP Poverty Reduction Strategy Paper
R&D Research and Development
RIP Regional Indicative Programme
SADC Southern Africa Development Community
TRIPs Agreement on Trade Related Aspects of Intellectual Property Rights
UN United Nations
UNAIDS United Nations Joint Programme on HIV/AIDS
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UNCTAD United Nations Conference on Trade and Development
UNICEF United Nations Children's Fund
WHO World Health Organisation
WIPO World Intellectual Property Organisation
WTO World Trade Organisation
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Annex 2: Matrix
INCREASE THE IMPACT OF EXISTING INTERVENTIONS
EXPECTED RESULTS INDICATIVE TIME
TABLE
PROGRESS STATUS 1.1.2003
1. The Commission will prioritise HAP interventions within overall development aid and increase support to ATM ( HIV/AIDS, Tuberculosis and
Malaria )
1.1.  First Round Programming CSPs/PRSPs finalised
1.1.1. Majority of CSPs (ACP/ALA-MEDA/OCTs) adopted;
HAP programmed 9th EDF ACP CSPs allocation increased to
15% (Abuja target);
1.1.2. PfA issues reflected in CSPs;
1.1.3. PfA issues reflected in PRSPs
1.1. End 2002
1.1.1. End 2004
1.1. Done
1.1.1. Ongoing. Current level HAP allocations programmed for 9th EDF –
ACP is 3.7%. ALAMEDA programming includes on average 40% for social
development support.
EP target of 35% of EC Budget committed to ‘social infrastructure’;
Renewed mid-term programming review cycle working towards expected
results (starting 2003);
1.1.2. Ongoing. Currently less than 5% of all CSPs reflect specific
HIV/AIDS, malaria, TB interventions;
1.1.3. Ongoing.
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1.2. PfA and Health and Poverty policies / resolutions adopted; 1.2. End 2002 1.2. Ongoing. Council resolution on PfA adopted on 14 May 2001; EP
resolution on PfA adopted on 4 October 2001; EC contribution to GFATM
regulation adopted on 23 October 2001; ACP-EU Joint Parliamentary
Assembly resolution adopted on 1 November 2001; EP adoption
contribution EC GFATM December 2001; Health and Poverty
Communication adopted March 2002 - Council resolution on Health and
Poverty adopted on 30 May 2002; EP report on Health and Poverty
Communication ongoing; Regulation on Poverty Diseases to be adopted
latest January 2003.
1.3.1. Programming and implementation 2002 special HIV/AIDS
budget line in line with PfA
1.3.2. Regulation 'Poverty Diseases' budget line revised,
including increase financial allocation.
1.3.3. HIV/AIDS integral part of Reproductive and Sexual Health
and Rights budget line.
1.4. EC staffing plan developed. Number of staff in HQ and
delegations responsible for health, AIDS and population
increased.
1.5. Partnerships with MS
1.6. Active participation in international for a
1.3. End 2002 1.3.1. Done. Call for Proposals launched August 2002.
1.3.2. Ongoing. Negotiations revised regulation Poverty Diseases B7-
6311. PDB 2003 includes 180% increase for special budget line (from €
25.3 to € 73.4 million).
1.3.3. Ongoing. Text revised regulation includes clear reference to
HIV/AIDS.
1.4. Ongoing. DEV B/3 HAP staff increased back to 1999 level. AIDCO
social development units adequately staffed. Staffing plan delegations to
be developed in light of discussions deconcentration.
1.5. Ongoing. ATM on agenda regular EU MS meetings. MS agreement to
use additional ODA for health, AIDS and population.
1.6. Ongoing. Programme for Action reflected in G8, EU/US, EU/Canada,
EU/Japan, Cairo Plan of Action negotiations; Durban, LDCIII, UNGASS
HIV/AIDS, Doha, Monterrey, Barcelona, Johannesburg.
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2. Commission services will provide specific guidance to EC geographical desks and delegations on policies, programming guidelines and the
implementation of the Programme for Action
2.1.1. Programming guidelines disseminated.
2.1.2. Proper e-correspondence network with Delegations.
2.2.1. Programming guidelines reviewed and updated.
2.1. End 2001
2.2. End 2002
2.1.1. Done.
2.1.2. Ongoing.
2.2.1. Ongoing.
3. The Commission will achieve more rapid disbursement and speed up and harmonise procedures
3.1. All HAP dormant programmes closed or re-identified.
3.2. HAP disbursement rates increased by 50%.
3.3. CRIS fully functional.
3.4. Four case studies on harmonisation of procedures
identified.
3.5. Other opportunities to direct unspent resources
(EDF/Budget) identified.
3.6. Opportunities for rapid resource transfers identified.
3.1. End 2001
3.2. End 2001
3.3. End 2002
3.4. End 2002
3.5. End 2002
3.6. End 2002
3.1. Ongoing.
3.2. Ongoing. HAP disbursement portfolio (1995-2000) was set at
17% May 2001, increased up to 23%.
3.3. ‘Health’ coding - according to DAC - and CRIS operations
ongoing
3.4. Missions - started September 2002 - in Mozambique,
Nicaragua, Morocco, Vietnam.
3.5. No progress.
3.6. No progress apart from GFATM process.
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4.The Commission will facilitate resources for innovative partnerships with international agencies and private sector
4.1. Active participation in the GFATM
4.2. Partnership with GAVI (TB/malaria vaccines)
4.3. Partnership with IAVI (HIV vaccine)
4.4. Strategic partnership with WHO (see 5)
4.5. Negotiations with UNICEF (malaria bednets - social
marketing)
4.6. Discussions with UNFPA / EIB / Condomi on condom
production
4.7. Negotiations with pharmaceutical industry on tiered
pricing
4.8. Co-operative agreement with World Bank/MS/WHO-
UNAIDS to provide technical input to country
programming and identification processes
End 2006 Negotiations revised regulation Poverty Diseases B7-6311 ongoing,
including proposal substantial increase financial resources for PfA
2003-2006. Additional resources programmed for 9th EDF intra-
ACP
4.1.Ongoing. EC GFATM Board Member. EC contribution of 120
million from 6-7th EDF and 2001 Budget.
4.2. Ongoing. Intense discussions in May 2002. Development plan
for countries to fill financing gaps for childhood vaccines from own
national budgets once GAVI has to face out;
4.3. Ongoing. Discussions in June 2002. Support for Medical
Research Council in South Africa through IAVI.
4.4. Ongoing. Programmed 9th EDF.
4.5. Initial discussions beginning 2002. Programmed from 9th EDF
4.6. Ongoing. Discussions with EIB August 2002. UNFPA no
progress as yet.
4.7. Ongoing. Regular discussions with industry. Lengthy
interservice meeting with GSK in March 2002. Pharma industry
part of TRADE consultation rounds.
4.8. Little progress. Proposal for Strategic Partnership with WHO
under discussion.
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5. Strengthening of pharmaceutical policies
5.1. Strategy in place for support for regional cooperation,
capacity building, financial and technical assistance, including
enhanced and improved essential drug policy and regulatory
schemes in ACP countries. Partnership with WHO strengthened.
5.1.1. Regional/sub-regional quality control laboratory networks
to ensure appropriate quality control of pharmaceuticals
developed.
5.1.2. Malaria protocols revised.
5.1.3. Essential drug policies refined in favour of developing
countries.
5.2. Other partners identified.
5.1. End 2002
5.1.1. End 2003
5.2. End 2002
5.1. Ongoing. Financing proposal € 25 million with WHO discussed at
EDF Committee November 2002, pending ratification 9th EDF.
5.1.1. Part of WHO partnership. Extension ARIVA
5.1.2. Progress on discussions on the change of national malaria protocols
in highly resistant countries (MSF).
5.1.3. Ongoing. WHO pre-qualification scheme for drugs/diagnostics for
AMT, revision of 11th WHO EDL includes non-generic key
pharmaceuticals. Discussion ongoing within GFATM Procurement Task
Force and newly-established GFATM Portfolio Management and
Procurement Committee.
5.2. GFATM work in progress
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6. Untying of Community aid
6.1. EC Memorandum on untying of aid.
6.2. Tender dossiers for ACP untied.
6.3. ALA regulation includes untying.
6.4. Communication untying discussed in Council/EP
6.5. EC aid for medicines and products for ATM fully untied.
6.1. End 2001
6.2. Mid 2002
6.3. Mid 2002
6.4. End 2002
6.5. End 2003
6.1. Done
6.2. Done. First case for Zimbabwe.
6.3. Done
6.4. Ongoing. Communication adopted November 2002.
6.5. Ongoing
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7. Developing technology transfer and local manufacturing capacity
7.1. Support identified for sector and market analyses;
dialogue, identification of existing business opportunities
for production of quality key pharmaceuticals - many of
which are off-patent.
7.2. Specific geographical focus on countries with pre-
existing local production capacity (in either private or
public sector).
7.3. Licensing agreements and business joint ventures
promoted through appropriate incentives.
7.4. Importance local production addressed in other
international fora.
7.5. Appropriate financing instruments identified
(PROINVEST, the investment promotion programme for
ACP countries, the EC-ACP Business Assistance Scheme
(EBAS)32, the private sector Investment Facility of the
Cotonou Agreement through the EIB, other EC technical
and financial cooperation mechanisms).
7.1. End 2003
7.2. End 2003
7.3. End 2004
7.4. End 2002
7.5. End 2002
7.1. Ongoing. Discussions with EIB/Condomi in August 2002 on
condom production linked with social marketing.
7.2. In progress.
7.3. Ongoing discussions with generic and R&D industry. UK High
Level Working group. Establishment ISG Incentives - Nov. 2002
7.4. Value local production acknowledged in UNGASS HIV/AIDS
- WHA G8 Okinawa Action Plan - AU Action Plan a/o.
Negotiations ongoing in GFATM - DDA
7.5. Revised legal base for special budget line for Poverty Diseases
2003-2006 to provide for additional resources. 9th EDF
programming entails provisions for local production. Other
instruments to be developed.
INCREASE AFFORDABILITY OF KEY PHARMACEUTICALS THROUGH A COMPREHENSIVE APPROACH
                                                
32 An ongoing programme for ACP businesses, which provides support to individual companies or producer associations in this sector.
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EXPECTED RESULTS INDICATIVE TIME
TABLE
PROGRESS STATUS
8. Lead international efforts to establish political commitment for a wide spread - voluntary and predictable tiered pricing mechanism
8.1. Political commitment EU MS and developing countries
8.2. Industry commitments to tiered pricing
8.3.  Tiered pricing part of GFATM policies and principles
8.4.  Tiered pricing as part of PfA back on G8 agenda
8.5. EU/US transnational agenda
8.6. EU/Canada agenda
8.7. EU/Japan
8.8. EU/AU - Cairo Plan of Action
8.9. Tiered pricing in OECD
8.10. Jburg Plan of Action
8.11. Close partnership with WHO/UNAIDS
8.1. End 2002
8.2. 2003
8.3. End 2002 - onwards
8.4. Mid 2003
8.5. End 2002
8.6. End 2001
8.7. End 2001
8.8. End 2001
8.9. End 2003
8.10 Mid 2002
8.11 Up to end 2006
8.1. Ongoing. Two Development Council resolutions. EC
participation in UK High Level Working Group on Access to
Medicines and in NL Access to Medicines debate.
8.2. Ongoing. GSK and Novartis made public commitments.
8.3. Ongoing. GFATM works according to ‘lowest possible prices’.
EC part of procurement working group. Work in progress on further
definition tiered pricing
8.4. Ongoing. Follow up to agreement in Okinawa (2000). Work in
progress for 2003 Summit in France.
8.5. Ongoing. No progress on TP since Gothenburg May 2001.
8.6. Done.
8.7. Done.
8.8. Done - ongoing preparations for Lisbon 2003
8.9. No progress
8.10. No result
8.11. Ongoing.
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9. Lead international efforts to establish arrangements for a wide spread, voluntary and predictable tiered pricing mechanism
9.1. Regulation against diversion tiered priced products into
EU (US) markets.
9.1.1. International concertation in place to contain the risk
of product diversion.
9.2. Mechanism defined for transparency and monitoring
9.3. Lower consumer prices in developing countries
9.1. First part 2003
9.1.1. End 2003
9.2. Mid 2003
9.3. End 2003
9.1 Ongoing. Adopted by Commission on 30 October 2002.
Council discussions with a view to adoption in first quarter 2003.
9.1.1. Discussions TRIPs Council on Doha Declaration paragraph 6.
9.2 Ongoing discussion EC/WHO, within UK high level working
group and most recently within GFATM Task Force on
procurement.
9.3. Ongoing33.
10. Analyse tariff data from DCs to assess basis for negotiations on reduction/abolition in Doha Round
10.1 Study on taxes, other duties and tariffs being finalised.
10.2. Information on importation, distribution and
registration fees available.
10.1. Early 2003
10.2. End 2002
10.1. Under preparation 34
10.2. Ongoing. Discussions ongoing in the GFATM Procurement
Task Force.
                                                
33 See: 'Untangling the Web of Price Reductions' - June 2002 - www.accessmed-msf.org - Médecins Sans Frontières.
34 See draft study 'Duties and Taxes on Essential Medicines used in the treatment of the major communicable diseases', DG TRADE F/4 July 2002.
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11. Support TRIPs application and discuss links between TRIPs Agreement and Public Health protection - Follow up to Doha Declaration on TRIPs and
Public Health
11.1 Broker different positions - get development deal for
Doha Round;
11.2 Work plan for reinforced TA on TRIPs
implementation for developing countries.
11.3 Technical assistance provided upon request /
according to plan.
11.4. Cooperation with WIPO reinforced.
11.1. End 2002
11.2. End 2003
11.3. End 2003
11.4. End 2002
11.1 Done. Doha Declaration on TRIPs and Public Health,
subsequent decision to allow LDCs to defer implementation of
pharma patents until 2016. Compulsory licenses export prohibition
regulated by end 2002.
EC position on Doha para's 6 and 7 developed and currently
discussed in TRIPs Council.
11.2. Ongoing. Study on TRIPs implementation in Sub-Saharan
Africa on tender stage. Mauritius requested a study on IP and TRIPs
at contract stage.
11.3. Ongoing.
11.4 No progress.
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INCREASE INVESTMENT IN RESEARCH AND DEVELOPMENT OF SPECIFIC GLOBAL PUBLIC GOODS
EXPECTED RESULTS INDICATIVE TIME
TABLE
PROGRESS STATUS
12. Strengthening support for Research and Development through increased support for basic and strategic research and the creation of a European
Development Clinical Trials Partnership
12.1 Sixth Framework Programme adopted.
12.2 EDCTP launched - essential EC development policy
principles reflected in set-up.
12.3. Fifth Framework Programme prioritises ATM.
12.1 Mid 2002
12.2 End 2002
12.1 Done. Commission proposal for 6th Framework Programme
adopted by EP and Council in first reading. Large support for
considerably increased earmarked R&D budget (€ 400 in total for
ATM, including € 200 million for EDCTP). DC countries can
participate with COM funding in all projects on the three diseases.
12.2 Ongoing. Preparation phase launched in April 2002. COM
proposal adopted in August 2002. Council and EP discussion end
2002. Steering Committee of the EDCTP will define modalities for
implementation based on development principles and with
significant involvement of DCs.
12.3. Fifth Framework Programme includes more than 77 ATM
R&D projects and programmes for more than € 109 million.
40
13. Capacity building in Developing Countries
13.1 Sixth Framework Programme includes focus on
capacity building including support for collaborative
molecular and clinical, epidemiological, operational and
social studies, strengthening the base for health-related
research. Emphasis put on gender balance and poverty
focus.
13.2 EDCTP includes issues of capacity building measures
such as: a) support for facilities and services at research
institutions and clinical institutions in developing countries,
b) human resources development,
13.1. End 2001
13.2 Mid 2003
13.1 Ongoing.
13.2. Ongoing. EDCTP foresees capacity building in the areas:
networking and cooperation; technology transfer; strengthen
clinical research capacities; initiate and develop clinical testing
facilities; finance training schemes for African scientists. € 150
million earmarked for capacity building.
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14. Incentives for the development of specific global public goods
14.1. The reform of the international financial architecture
to foster increased availability and development of global
public goods promoted.
14.2 Incentive package examined and developed (extension
of patent protection/marketing rights – venture capital - low
cost loans – tax credits – guaranteed markets, etc.).
14.3 Regulatory aspects developed.
14.4 Economic research demand completed.
14.5 Joint financing mechanisms developed.
14.6 EU AIDS Vaccine Task Team strengthened.
14.7 Partnership with IAVI strengthened.
14.8 Partnership and continuing co-operation with EMEA
14.1. End of 2002
14.2 End 2003
14.3 End 2002
14.4 End 2002
14.5 End 2003
14.6 End 2003
14.7 End 2003
14.8 End 2003
14.1.1 Ongoing work in relation to UN special task force on GPGs
14.1.2 OECD work on GPGs for health
14.1.3 Work within GFATM progressing rapidly
14.2 Ongoing discussions with industry.
Work with UK High Level Working Group on Access to
Medicines.
14.3 No progress. Discussions on involving regulatory bodies in
DCs in the EDCTP.
14.4 Ongoing research with the World Bank. First results discussed
in June 2002.
14.5 Ongoing. GFATM effort. Little progress on additional efforts
(linked to special GPG task force)
14.6 Ongoing. Last meeting June 2002.
14.7 Ongoing
14.8 Ongoing
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Annex 3: The Millennium Development Goals
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Annex 4: Price and price reductions for certain HIV/AIDS and Malaria products
The Programme for Action recognises that the price of pharmaceuticals is only one element in
the fight against HIV/AIDS, malaria and TB. Complementary action is needed in all other
areas identified in the Programme for Action, including sustainable financing, the
strengthening of health systems, and the focus on improved health outcomes through sectors
other than health.
The last two years many pharmaceutical manufacturers reduced their prices for
pharmaceuticals sold in developing countries. This change has been generated by the global
and public focus, including by the EU, on ‘affordability of medicines’, as well as by the
prospect of competition by generic manufacturers. Price reductions have included not only
pharmaceuticals for HIV/AIDS but also for malaria and other diseases.
Price reductions are the result of number of factors such as 1) voluntary bilateral agreements,
2) bulk purchasing, 3) voluntary licensing, 4) compulsory licensing / or threat to use
compulsory licensing, and 5) generic production.
Examples of voluntary agreements include; those between six participating firms and
countries to supply anti-retrovirals drugs, through the UN sponsored Accelerated Access
Initiative (launched in 2000 and currently covering about 1% of those needing treatment);
agreements between the pharmaceutical company Novartis, South Africa and WHO currently
on a pilot basis (24,000 people covered) for the tiered priced malaria medication, Coartem;
and a partnership coming on stream between GSK and WHO for the Anti-malarial
LAPDAP35.
                                                
35 See for more detail: Background paper to the UK High Level Working Group ‘Differential Pricing of
Essential Medicines in the Developing World’, London, 26 July 2002.
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The table below gives estimated price reductions for anti-retroviral drugs (ARVs).
Estimated price reductions offered to certain developing countries compared to retail price 
VAT exluded in Switzerland (November 2002)
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Nelfinavir (Roche)
Amprenavir (GSK)
Saquinavir (Roche)
Nevirapine (BI)
Zidovudine (GSK)
Lamivudine & Zidovudine (GSK)
Indinavir (MSD)
Efavirenz (MSD & BMS)
Didanosine (BMS)
Ritonavir (Abbott)
Lamivudine (GSK)
Stavudine (BMS)
Source: MSF, November 2002
Coartem has been registered under two different brand names with different prices and
different packaging. It segments the market providing a drug for OECD markets, one for the
private sector of malaria endemic countries and a third product available through WHO for
use in the public sector. The likely constraint to reaching scale may be i) that the substantially
reduced price is only available through the public sector, patients (including the poor) access
malaria medications primarily through the private sector, and ii) the incentive and feasibility
for leakage from poor to wealthy markets within poor countries.
